SEC Tracker
Get the app

Alumis ALMS

Alumis FY 2024: net loss $294.2M; diluted EPS −$10.38

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Alumis reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$294.2MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Diluted EPS−$10.38No year-earlier figure tagged10-K income statement, on EDGAR
  3. Cash and cash equivalents$169.5MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$255.1MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Alumis files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  2. Editas Medicine EDIT public float $191M, Jun 30, 2025
  3. Omeros OMER public float $172M, Jun 30, 2025
  4. Palvella Therapeutics PVLA public float $197M, Jun 30, 2025
  5. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025